Novartis AG vs Teva Pharmaceutical Industries Limited: A Gross Profit Performance Breakdown

Novartis vs. Teva: A Decade of Gross Profit Trends

__timestampNovartis AGTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20143628900000011056000000
Thursday, January 1, 20153298300000011356000000
Friday, January 1, 20163191600000011859000000
Sunday, January 1, 20173296000000010825000000
Monday, January 1, 2018347590000008296000000
Tuesday, January 1, 2019342520000007536000000
Wednesday, January 1, 2020347770000007725000000
Friday, January 1, 2021370100000007594000000
Saturday, January 1, 2022363420000006973000000
Sunday, January 1, 2023341880000007646000000
Monday, January 1, 2024388950000008064000000
Loading chart...

Unleashing insights

A Decade of Gross Profit: Novartis AG vs. Teva Pharmaceutical

In the competitive landscape of the pharmaceutical industry, Novartis AG and Teva Pharmaceutical Industries Limited have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Novartis AG consistently outperformed Teva, with an average gross profit nearly four times higher. Novartis's peak performance was in 2021, with a gross profit of approximately $37 billion, marking a 15% increase from its lowest point in 2016. In contrast, Teva's gross profit saw a significant decline, dropping by 37% from its 2016 peak to its lowest in 2022. This trend highlights the challenges Teva faced, possibly due to market dynamics and strategic shifts. As the pharmaceutical sector evolves, these figures underscore the importance of strategic agility and market adaptation for sustained financial health.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025